To investigate if this inhibitor hits the expected targets, Pim kinases, and exhibits anti-proliferative activity in Myc-induced lymphomas, we treated the mouse B-cell lymphoma cell lines Eμ239 and λ820 with Pimi and Pim-ci, a 1000-fold less potent Pim inhibitor from the same chemical series. The gene discussed is MYC; the disease is B-cell non-Hodgkin lymphoma.